MAPT and Alzheimer disease: Prior studies suggested that biomarker dynamics differ in AD, with both CSF and plasma Aβ42/40 ratio starting to change before p-tau [26], p-tau levels continuing to increase as AD pathology accumulates [40], and the increases in p-tau in magnitude being considerably larger than the decrease of Aβ42/40 ratio [12, 26].